AERI News Alert Aerie Pharmaceuticals Inc (AERI) 28.04 12/17/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aerie Pharmaceuticals Inc (AERI) 28.04 $AERI

Aerie Pharmaceuticals Added to NASDAQ Biotechnology Index (NBI)
Business Wire - Tue Dec 16, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that it has been selected for addition to the NASDAQ Biotechnology Index(R) (NASDAQ:^NBI), which will become effective upon market open on Monday, December 22, 2014.
IBB: 293.67 (-3.99), AERI: 28.04 (-1.08)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 30.02 (+0.70), ZSPH: 44.19 (-2.83), AMRN: 1.03 (-0.02), OPHT: 45.94 (+0.36), AERI: 28.04 (-1.08), ASPX: 25.09 (+0.78), CNCE: 10.58 (+0.11), ICEL: 5.41 (+0.14), GWPH: 67.64 (-0.49), AUXL: 32.75 (-0.01), RTRX: 11.12 (+0.56), RCPT: 114.46 (-0.67), AAVL: 50.79 (-0.48), AKBA: 11.03 (+0.44), EXPR: 13.63 (+0.04), RARE: 40.65 (+0.89), RLYP: 31.59 (-1.40), PETX: 11.88 (-0.71), ENTA: 41.14 (-1.97), RDUS: 26.30 (+1.20), CARA: 9.54 (-0.19), FLML: 16.48 (+0.27), ALIM: 5.47 (+0.13), ANIP: 55.08 (+1.32), ICPT: 129.30 (-4.61), RVNC: 16.46 (+0.12), POZN: 9.03 (+0.10), FPRX: 21.92 (+0.07), ZFGN: 21.67 (-0.08), CRIS: 1.15 (-0.01), QLTI: 3.41 (-0.03), PCYC: 129.56 (+1.12), PTX: 9.20 (+0.06), CLDN: 17.76 (+0.03), RIGL: 2.12 (+0.01), HPTX: 21.60 (-0.06), AMPH: 11.28 (+0.25), INO: 8.34 (+0.08), VSAR: 19.17 (+0.11), FMI: 20.73 (-0.15), TBPH: 13.48 (-0.13), XLRN: 37.63 (-0.37), MGNX: 28.79 (-0.20), INSM: 13.70 (-0.13), ONTX: 3.94 (-0.12), ALDR: 24.79 (-0.77), SAGE: 37.66 (+3.29), KITE: 52.49 (-1.41), CGEN: 7.98 (-0.01), FOLD: 7.73 (-0.15), KPTI: 31.07 (-0.82)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 30.02 (+0.70), ZSPH: 44.19 (-2.83), AMRN: 1.03 (-0.02), OPHT: 45.94 (+0.36), AERI: 28.04 (-1.08), ASPX: 25.09 (+0.78), CNCE: 10.58 (+0.11), ICEL: 5.41 (+0.14), GWPH: 67.64 (-0.49), AUXL: 32.75 (-0.01), RTRX: 11.12 (+0.56), RCPT: 114.46 (-0.67), AAVL: 50.79 (-0.48), AKBA: 11.03 (+0.44), EXPR: 13.63 (+0.04), RARE: 40.65 (+0.89), ZGNX: 1.11 (-0.03), RLYP: 31.59 (-1.40), PETX: 11.88 (-0.71), ENTA: 41.14 (-1.97), RDUS: 26.30 (+1.20), CARA: 9.54 (-0.19), FLML: 16.48 (+0.27), ALIM: 5.47 (+0.13), ANIP: 55.08 (+1.32), ICPT: 129.30 (-4.61), RVNC: 16.46 (+0.12), POZN: 9.03 (+0.10), NDAQ: 45.74 (-0.72), FPRX: 21.92 (+0.07), CRIS: 1.15 (-0.01), ZFGN: 21.67 (-0.08), QLTI: 3.41 (-0.03), PCYC: 129.56 (+1.12), PTX: 9.20 (+0.06), CLDN: 17.76 (+0.03), RIGL: 2.12 (+0.01), HPTX: 21.60 (-0.06), AMPH: 11.28 (+0.25), INO: 8.34 (+0.08), VSAR: 19.17 (+0.11), FMI: 20.73 (-0.15), TBPH: 13.48 (-0.13), XLRN: 37.63 (-0.37), MGNX: 28.79 (-0.20), INSM: 13.70 (-0.13), ONTX: 3.94 (-0.12), ALDR: 24.79 (-0.77), SAGE: 37.66 (+3.29), KITE: 52.49 (-1.41), CGEN: 7.98 (-0.01), FOLD: 7.73 (-0.15), KPTI: 31.07 (-0.82)

Spin Doctors; Data And Market Projections From Aerie Pharmaceuticals, Inc. Are Too Optimistic
Sirius Capital - Seeking Alpha - Fri Dec 12, 7:00AM CST
During the Cold War era there was a famous joke about a race between a US and a USSR runner in which the American crossed the finish line first. The headline in the Communist party newspaper 'Pravda' had read 'In an international race, the Soviet...
AERI: 28.04 (-1.08)

Aerie Pharma completes enrollment in Rhopressa Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 7:47AM CST

AERI: 28.04 (-1.08)

Aerie Pharmaceuticals Completes Enrollment in Phase 3 Registration Trial ("Rocket 1" of Rhopressa(TM), Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma
Business Wire - Tue Dec 02, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the completion of enrollment in the Company's 400-patient Phase 3 registration trial ("Rocket 1" of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Rocket 1 and a second Phase 3 registration trial ("Rocket 2" will measure efficacy over three months. The primary efficacy endpoint of the trials is to demonstrate non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol. Timolol is the most widely used comparator in registration trials for glaucoma. In addition, the Company is conducting a safety-only study in Canada, named "Rocket 3."
AERI: 28.04 (-1.08)

Aerie Pharmaceuticals to Present at the Piper Jaffray 26th Annual Healthcare Conference
Business Wire - Mon Nov 24, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Richard Rubino, chief financial officer, will present in a fireside chat discussion at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 11:30 a.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business update.
AERI: 28.04 (-1.08)

Aerie Pharmaceuticals to Present at the 2014 Stifel Nicolaus Annual Healthcare Conference
Business Wire - Wed Nov 12, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the 2014 Stifel Nicolaus Annual Healthcare Conference on Tuesday, November 18, 2014 at 8:35 a.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
AERI: 28.04 (-1.08)

Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:40PM CST

AERI: 28.04 (-1.08)

Aerie posts 3Q loss
Automated Insights - Tue Nov 11, 3:27PM CST
RESEARCH TRIANGLE PARK, N.C. (AP) _ Aerie Pharmaceuticals Inc. (AERI) on Tuesday reported a loss of $13.1 million in its third quarter.
AERI: 28.04 (-1.08)

Aerie Pharmaceuticals misses by $0.13
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:13PM CST

AERI: 28.04 (-1.08)

Aerie Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Business and Product Development Update
Business Wire - Tue Nov 11, 3:05PM CST
--Rhopressa(TM) and Roclatan(TM) Development Programs Advancing
AERI: 28.04 (-1.08)

Aerie Pharma reports November 11
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:07AM CDT

AERI: 28.04 (-1.08)

Aerie Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014
Business Wire - Tue Oct 28, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its third quarter 2014 financial results will be released after the market closes on Tuesday, November 11, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
AERI: 28.04 (-1.08)

Aerie Pharmaceuticals names Dr Benjamin F. McGraw to board
M2 - Tue Oct 07, 7:01AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) revealed on Monday the addition of Benjamin F. McGraw, III, PharmD to its board of directors and as a member of its Audit Committee, effective 30 September 2014.
AERI: 28.04 (-1.08)

Aerie Pharmaceuticals Elects Benjamin F. McGraw, III to Its Board of Directors
Business Wire - Mon Oct 06, 3:45PM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that Benjamin F. McGraw, III, Pharm.D., has been elected to the Company's Board of Directors and as a member of the Audit Committee, effective September 30, 2014. Dr. McGraw brings more than 30 years of experience in the life sciences, responsible for advancing breakthrough technologies and numerous development-stage programs through commercialization.
AERI: 28.04 (-1.08)

Aerie Announces Closing of $125 Million Convertible Notes Financing
Business Wire - Tue Sep 30, 3:05PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has closed its $125 million financing with Deerfield Management Company L.P. ("Deerfield" , a current Aerie shareholder. Under the terms of the financing, the notes are secured and will accrue interest at a rate of 1.75% per annum until maturity in September of 2021. The notes are convertible at a conversion price representing a 30% premium over the closing price of Aerie stock on September 8, 2014, resulting in a conversion price of $24.80 per share.
AERI: 28.04 (-1.08)

Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 28.04 (-1.08)

Aerie expects USD125m from convertible notes financing
M2 - Tue Sep 09, 6:42AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) revealed on Tuesday the receipt of a USD125m financing commitment from its current shareholder, Deerfield Management Company.
AERI: 28.04 (-1.08)

Deerfield Management Company Announces a $125 Million Facility with Aerie Pharmaceuticals
Business Wire - Tue Sep 09, 5:03AM CDT
Deerfield Management Company announced today it has committed to invest $125 million in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) through senior secured convertible notes. The financing is expected to be funded before the end of September 2014, subject to customary closing conditions. The facility provides Aerie with capital for the continued advancement of development activities for the Company's clinical-stage product pipeline, general corporate purposes and strategic growth opportunities.
AERI: 28.04 (-1.08)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 295

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 112

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 196

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 98

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 176

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 184

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 210

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 168

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 137

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Merit Medical Systems: Price Target Raised Amid Strong Growth Prospects

Updated Category News Views 92

Merit Medical Systems Price Target Increased by Baird Baird has enhanced its price target for Merit Medical Systems, Inc. (NASDAQ: MMSI) from $96.00 to $107.00, keeping an Outperform rating on the stock. This adjustment anticipates that the company will surpass its organic growth rate and earnings per share (EPS) expectations for the upcoming quarter. Confidence in Future...

Continue Reading
Qualifacts Is Enhancing Collaborative Workspaces in Tampa

Updated Category News Views 122

Qualifacts Consolidates Tampa Operations into a Modern Office Qualifacts, a prominent player in the field of electronic health records (EHR) and data solutions tailored for behavioral health and human services organizations, has made a significant move by consolidating its two smaller offices in Tampa. The company has transitioned into a new, modern location designed to...

Continue Reading
Unlocking the Potential of Neuromarketing for Digital Strategies

Updated Category News Views 140

Understanding Neuromarketing and Its Impact In today's competitive landscape, businesses are continuously seeking ways to enhance their digital marketing strategies. One approach gaining momentum is neuromarketing, which delves into the psychology behind user behavior. A recent article from Digital Silk explores how neuromarketing principles can guide organizations in...

Continue Reading
Monkee's of Loudoun Opens to Cheers and Elegance

Updated Category News Views 187

Bringing Southern Charm to Loudoun We've all seen those places where people parade in with snooty airs and pricetags that could feed a family for a week, but this one feels different. Monkee’s of Loudoun isn’t just rolling in the racks of high fashion — it’s bringing the allure of the South with a sprinkle of luxury and empathy. This franchise is no amateur,...

Continue Reading
PG&E Critiques Senate Bill 492's Wildfire Solutions

Updated Category News Views 60

PG&E's Take on Senate Bill 492: More to Be Desired Sit down for a moment, because PG&E's not mincing words with their latest statement. Talking about Senate Bill 492, PG&E puts it plain and clear—this legislation is just skirting around the edges of what's really needed to tackle California's wildfire crisis. In their eyes, it's like putting a band-aid on a wound that...

Continue Reading